Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Amgen, Selexis Expand R&D License Agreement | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Amgen, Selexis Expand R&D License Agreement

Will evaluate the SURE CHO-M Cell Line for R&D

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amgen has expanded its R&D license agreement with Selexis SA to include an evaluation of Selexis’ SURE CHO-M Cell Line for R&D. Amgen will be able to evaluate the SURE CHO-M Cell Line in conjunction with the Selexis SUREtech Vectors for improved R&D. 
 
“Successful protein expression in R&D is dependent upon a cell line development platform that is robust, high-yielding and stable,” said Igor Fisch, Ph.D., president and chief executive officer of Selexis. “Selexis is continually optimizing its proprietary cell line and technology platform to enable partners such as Amgen to make better R&D decisions by generating reliable data points faster and more cost efficiently.  This current agreement is built on the long-standing relationship between our two companies since 2004.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics